Lipid-based nanotherapeutics for siRNA delivery

Purpose: RNAi has strong therapeutic potential, but clinical translation of siRNA is limited by delivery. siRNA is large, negatively charged, susceptible to nuclease degradation, poorly taken up by cells, and must reach the cytoplasm to engage RISC. Safe and effective lipid-based delivery systems are needed to protect siRNA, promote cellular uptake, enable endosomal escape, and release functional siRNA intracellularly.

Hypothesis: If lipid-based nanocarriers are designed with optimized molecular and structural parameters—including cationic or ionizable lipids, cholesterol, PEG shielding, pH-sensitive groups, controlled size below ~100 nm, and appropriate surface charge—then they can protect siRNA in circulation, deliver it to target cells, facilitate endosomal escape, and produce effective RNAi-mediated gene silencing.

Aims: Review the molecular and structural parameters of lipid-based siRNA delivery systems. - Discuss cationic/anionic lipids, cholesterol, carrier charge, size, shape, and biodistribution. - Describe cellular uptake, endosomal escape mechanisms, and pH-sensitive strategies. - Summarize the clinical status and future prospects of lipid-based siRNA nanotherapeutics.

Delivery system: Platform: lipid-based nanotherapeutics for siRNA delivery, including lipoplexes, liposomes, lipid-like materials (lipidoids), and lipid-coated polyplexes. - Payload: small interfering RNA (siRNA), typically 21–23 nucleotides. - Key cationic lipids: DOTMA, DOTAP, Transfectam®, 98N12-5; lipidoids with multiple amines, amide linkers, and C8–C12 acyl chains. - Other components: cholesterol, helper lipids, PEG-lipids, pH-sensitive lipids such as citraconyl-DOPE, and anionic lipids for coating cationic polyplexes. - Targeting/functionalization: galactose derivatives for asialoglycoprotein receptor, T7 phage peptides, transferrin, folate, and PEG shielding. - Design features: size <100 nm for hepatocyte/tumour/inflamed-tissue targeting; neutral or PEG-shielded surface to reduce RES uptake; pH-sensitive or fusogenic components for endosomal escape.

Approach: Review and synthesis of in vitro, in vivo, and clinical literature. Cited models include C. elegans, mammalian cells, mouse tumour models, autoimmune arthritis models, multiple sclerosis models, and human clinical trials in age-related macular degeneration, RSV, hypercholesterolemia, and solid tumours. As a review, it reports no primary experimental groups, n values, doses, or controls.

Key methods: No primary methods. The review discusses data generated by cited studies using: - siRNA complexation and lipoplex structural analysis. - Endocytosis pathway inhibition and colocalization studies. - Gene silencing/knockdown assays. - Biodistribution and pharmacokinetic analysis. - Cholesterol depletion and membrane fusion assays. - Clinical trial safety and activity readouts.

Key results: siRNA duplexes are 21–23 nucleotides, about 7.5 nm long and 2 nm in diameter, with a molecular weight of roughly 13 kDa. - Knockdown duration is often 3–7 days in dividing cells and up to 3–4 weeks in non-dividing cells. - About 95% of DharmaFECT siRNA lipoplexes enter cells by endocytosis; ~50% is clathrin-mediated, and ~20% of remaining cytoplasmic delivery involves lipid-raft/caveolin-mediated endocytosis. - Cholesterol depletion from cell membranes completely abolished siRNA uptake and transfection in one study. - Carriers <100 nm accumulate more in tumours, hepatocytes, and inflamed tissue; larger particles are taken up by Kupffer cells or RES. - Lipidoid structural features linked to high knockdown: more than two amines per head, amide bonds, more than two acyl chains, acyl chains of 8–12 carbons, and at least one secondary amine. - Gold nanoparticle uptake followed a bell-shaped size dependence, with most efficient uptake at ~50 nm. - Filomicelles persisted in rodent circulation for up to 1 week, about 10 times longer than spherical counterparts. - Clinical trials include siRNA-liposomal formulations targeting PKN3, KSP/VEGF, ApoB, and others.

Interpretation: The authors conclude that lipid-based carriers are promising for therapeutic siRNA delivery. They emphasize that both molecular-scale design—lipid structure, amine valency, charge, cholesterol, PEG, pH sensitivity—and meta-molecular design—particle size, shape, surface charge, and biodistribution—must be considered. Carriers <100 nm with PEG shielding and efficient endosomal escape are likely necessary for successful systemic siRNA therapy.

Limitations: Review article; no primary data, effect sizes, n values, doses, or controls. - Endosomal escape mechanisms remain incompletely understood and controversial. - Cationic lipids can cause toxicity, nonspecific knockdown, and RES uptake. - PEGylation improves circulation but may reduce cellular uptake. - Larger particles are cleared by Kupffer cells/RES; optimal size is context-dependent. - Shape effects on delivery are underexplored. - Most clinical data are early-stage; translation from rodents/primate models to humans remains uncertain. - siRNA stability, off-target effects, and repeated dosing require further optimization.